Abacus Health Products Announces Revised Release Date for 2019 Second Quarter Financial Results, Conference Call and Webcast

Conference Call & Live Audio Webcast Details:

All interested parties can join the conference call by dialing 1.877.800.8397 or 1.615.622.8055, conference ID: 6949749.

A live audio webcast of the conference call will also be available at: https://engage.vevent.com/rt/abacushealthproductsinc/index.jsp?seid=11

Please dial-in or connect at least 15 minutes prior to the conference call to ensure a secure line and adequate time for any software download that may be required to join the webcast.

Archived Replay:

For those parties unavailable to attend, the conference call will be archived for replay until midnight ET, September 26, 2019. To access the archived conference call, please dial 1.855.859.2056 or 1.404.537.3406 and enter the conference ID 6949749. An archived replay of the webcast will be available for 30 days by clicking the link above.

About Abacus Health Products, Inc.

Abacus is a company engaged in the development and commercialization of over-the-counter (OTC) registered topical medications with active pharmaceutical ingredients and which contain organic and natural ingredients, including a cannabinoid-rich hemp extract containing CBD from Cannabis sativa L plant. Abacus’ products are aimed at the rapidly growing markets for topical pain relief and therapeutic skincare and are based on proprietary patent-pending technologies developed by Abacus. Abacus’ formulations combine advanced science with organic and natural ingredients to provide safe relief. Abacus currently offers two lines of products: (i) CBD CLINIC™, marketed to the professional practitioner market, and (ii) CBDMEDIC™, marketed to the consumer market. Abacus’ products are offered across the United States and are produced by a contract manufacturer in a cGMP compliant and audited manufacturing facility.

To learn more about Abacus, visit www.abacushp.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190821005678/en/